Derudas D. Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS. Mediterr J Hematol Infect Dis [Internet]. 2025 Feb. 27 [cited 2025 Mar. 12];17(1):e2025025. Available from: https://www.mjhid.org/mjhid/article/view/5946